Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹139 Cr.
Stock P/E
91.4
P/B
5.3
Current Price
₹200
Book Value
₹ 37.6
Face Value
10
52W High
₹226.7
52W Low
₹ 81.9
Dividend Yield
0%

Choksi Laboratories Overview

Business

Choksi Laboratories Ltd. is primarily engaged in providing analytical testing services across various sectors. The company operates as a contract research and testing organization (CRTO), offering chemical, biological, and instrumental analysis of a wide range of products and materials. Their core services include quality control testing, regulatory compliance testing, environmental monitoring, and R&D support for industries such as pharmaceuticals, food and agro products, water, environmental samples, minerals, metals, and construction materials. The company makes money by charging fees for these specialized testing services, based on the type, complexity, and volume of analysis performed for its clients.

Revenue Mix

While specific revenue segmentation by industry is not always granularly disclosed, Choksi Laboratories' services can be broadly categorized by the sectors they serve:

Pharmaceutical & Healthcare Testing (Raw materials, finished products, stability studies, impurity profiling)

Food & Agricultural Product Testing (Nutritional analysis, contaminant testing, pesticide residues)

Environmental Testing (Water, wastewater, air, soil analysis)

Material Testing (Minerals, metals, construction materials)

These segments contribute based on the demand from respective industries for quality assurance and regulatory adherence.

Industry

Choksi Laboratories operates within the Testing, Inspection, and Certification (TIC) industry, which falls under the broader "Business Support" sector. The Indian TIC market is driven by increasing regulatory compliance, quality consciousness, and growth in manufacturing and exports. The industry is fragmented, with global majors (e.g., SGS, Bureau Veritas, Intertek) and numerous domestic players, ranging from large specialized labs to smaller regional ones. Choksi Laboratories is an established domestic player, particularly strong in Western India, known for its accreditations (like NABL) and range of analytical services, positioning itself as a reliable partner for industries seeking compliance and quality assurance.

MOAT

Accreditations & Certifications: Critical industry-specific accreditations (e.g., NABL - National Accreditation Board for Testing and Calibration Laboratories, ISO certifications, GLP) are significant barriers to entry, enhancing credibility and trust.

Specialized Expertise & Reputation: A long operating history and established reputation for reliable and accurate results build client trust and repeat business.

Capital-Intensive Infrastructure: Investing in advanced analytical equipment and infrastructure requires significant capital, which can deter new entrants.

Client Relationships: Established long-term relationships with industrial clients across diverse sectors.

Growth Drivers

Increasing Regulatory Scrutiny: Stricter quality and safety regulations from Indian and international bodies for food, pharmaceuticals, and environmental standards.

Growth in Manufacturing & Exports: Expanding manufacturing output and export activities in India necessitate more robust quality control and compliance testing.

Outsourcing Trend: Companies increasingly outsource analytical testing to specialized labs to gain objectivity, reduce in-house costs, and leverage expert capabilities.

Consumer Awareness: Growing consumer demand for high-quality, safe, and transparently tested products.

Healthcare & Pharmaceutical Sector Growth: India's booming pharmaceutical and healthcare industries drive consistent demand for drug testing and analysis.

Risks

Intense Competition: High competition from large multinational TIC players and a multitude of smaller, regional laboratories.

Technological Obsolescence & Capex: Continuous need for investment in new, advanced analytical equipment and technologies to remain competitive and meet evolving testing standards.

Regulatory Changes: Adverse changes in testing standards, accreditation requirements, or industry-specific regulations could impact operations and compliance costs.

Economic Downturn: Reduced industrial activity or slowdowns in key client sectors (e.g., pharma, food processing) can lead to decreased demand for testing services.

Manpower & Skill Shortage: Availability and retention of highly skilled scientific and technical personnel for complex analytical tasks.

Litigation Risk: Potential for legal liabilities arising from inaccuracies in testing results or data integrity issues.

Management & Ownership

Choksi Laboratories Ltd. is a promoter-led company, with the Choksi family playing a significant role in its management and ownership. The promoters typically hold a substantial stake, indicating aligned interests with the company's long-term performance. Management quality is generally seen as experienced within the analytical testing domain, having guided the company through its operational history and regulatory landscape. The ownership structure reflects a typical Indian family-controlled enterprise, with the public holding the remaining shares.

Outlook

Choksi Laboratories Ltd. operates in a sector with structural tailwinds driven by India's industrial growth, heightened regulatory focus on quality, and increasing outsourcing trends. The company's established accreditations and diverse service portfolio position it to benefit from these drivers, particularly in the pharmaceutical and food sectors. However, the outlook is balanced by intense competition from both domestic and international players, the necessity of continuous capital expenditure for technological upgrades, and the potential impact of economic fluctuations on industrial demand. Maintaining its reputation for reliability, expanding its service offerings, and navigating the evolving regulatory environment will be crucial for sustained growth and profitability.

Choksi Laboratories Share Price

Live · BSE · Inception: 1993
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Choksi Laboratories Quarterly Results

#(Fig in Cr.) Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 11 11 9 10 11 11 11 11 13 12
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 11 11 9 10 11 11 11 11 13 12
Total Expenditure 8 8 7 8 8 8 8 8 9 9
Operating Profit 4 3 2 3 4 3 3 3 4 3
Interest 1 1 1 1 1 1 1 1 1 1
Depreciation 1 2 2 2 2 2 2 2 2 2
Exceptional Income / Expenses 0 0 0 0 0 0 0 1 0 0
Profit Before Tax 1 1 0 0 1 1 1 1 1 1
Provision for Tax 1 0 0 0 0 0 0 1 0 0
Profit After Tax 1 0 0 0 1 0 0 0 1 1
Adjustments -0 0 0 0 0 0 0 0 0 -0
Profit After Adjustments 1 0 0 0 1 0 0 0 1 1
Adjusted Earnings Per Share 1 0.6 0.1 0.2 1.3 0.6 0.3 0.4 1.5 0.8

Choksi Laboratories Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 22 22 29 31 34 28 26 30 34 37 42 47
Other Income 1 0 1 0 0 0 0 0 0 0 0 0
Total Income 23 22 30 32 34 28 26 30 35 37 42 47
Total Expenditure 17 17 24 25 26 25 22 21 24 26 30 34
Operating Profit 6 5 6 7 8 3 5 9 10 10 11 13
Interest 2 1 1 2 2 2 3 3 4 3 3 4
Depreciation 3 3 3 3 4 5 5 5 5 6 6 8
Exceptional Income / Expenses 0 0 0 0 0 -2 0 0 2 0 0 1
Profit Before Tax 1 1 1 2 2 -6 -3 0 4 2 2 4
Provision for Tax 0 0 0 1 1 -2 -0 0 1 1 1 1
Profit After Tax 1 1 1 1 2 -4 -3 0 3 1 2 2
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 1 1 1 1 2 -4 -3 0 3 1 2 2
Adjusted Earnings Per Share 1.3 1 1.3 1.9 2.3 -5.6 -3.7 0.3 4.6 1.6 2.2 3

Choksi Laboratories Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 19 20 21 22 24 20 18 18 21 22 24
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 6 8 4 6 14 27 29 28 24 18 15
Other Non-Current Liabilities 1 1 1 1 4 2 2 2 2 3 2
Total Current Liabilities 12 14 14 16 13 14 16 16 13 19 24
Total Liabilities 38 43 41 45 55 64 65 63 59 62 65
Fixed Assets 19 18 20 26 35 33 50 47 45 43 48
Other Non-Current Assets 4 10 8 4 4 14 1 2 1 4 1
Total Current Assets 15 15 13 15 16 17 13 14 14 15 16
Total Assets 38 43 41 45 55 64 65 63 59 62 65

Choksi Laboratories Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 1 1 1 1 0 0 0 0 0 1
Cash Flow from Operating Activities 2 7 7 6 7 3 6 8 8 12 12
Cash Flow from Investing Activities -1 -7 -2 -5 -10 -14 -8 -3 -1 -7 -8
Cash Flow from Financing Activities -1 1 -5 -1 2 11 2 -5 -8 -5 -4
Net Cash Inflow / Outflow 0 0 -0 0 -1 0 -0 0 -0 0 -0
Closing Cash & Cash Equivalent 1 1 1 1 0 0 0 0 0 1 1

Choksi Laboratories Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 1.27 1.04 1.28 1.93 2.3 -5.58 -3.74 0.3 4.61 1.59 2.19
CEPS(Rs) 5.33 4.96 5.39 6.48 7.58 0.97 2.86 8.09 12.5 9.8 11.52
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 27.73 28.76 30.33 32.15 34.47 29.03 25.48 25.7 30.31 31.89 33.89
Core EBITDA Margin(%) 23.36 22.79 16.62 17.97 21.53 10.09 16.06 29.65 29.8 28 27.06
EBIT Margin(%) 13.41 10.61 9.66 10.01 11.36 -13.58 0.04 11.98 21.02 12.88 11.67
Pre Tax Margin(%) 6.27 5.11 4.55 5.49 6.8 -20.29 -10.93 1.22 10.81 4.53 5.15
PAT Margin (%) 4.01 3.24 3.1 3.83 4.74 -13.8 -10.15 0.69 9.32 3.02 3.65
Cash Profit Margin (%) 16.89 15.49 13.06 12.81 15.64 2.41 7.77 18.76 25.28 18.59 19.2
ROA(%) 2.31 1.8 2.15 3.16 3.2 -6.53 -4.06 0.32 5.24 1.83 2.41
ROE(%) 4.45 3.67 4.34 6.19 6.9 -17.57 -13.74 1.16 16.46 5.12 6.65
ROCE(%) 9.39 7.32 8.41 10.49 10.14 -8.27 0.02 6.75 13.9 9.18 9.45
Receivable days 129.38 139.36 110.28 96.82 100.96 102.27 107.63 112.09 110.99 104.68 94.63
Inventory Days 0 0 2.93 2.7 3.76 3.78 2.05 2.2 2.43 2.85 4.02
Payable days 6509.88 12405.93 541.1 549.74 591.84 763.82 800.65 813.96 479.72 408.62 551.15
PER(x) 5.98 10.61 13.31 13.39 6.11 0 0 85.46 7.26 26.6 54.94
Price/Book(x) 0.27 0.38 0.56 0.81 0.41 0.28 0.31 0.99 1.1 1.33 3.55
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 0.73 0.92 0.78 0.95 0.78 1.31 1.61 1.73 1.55 1.58 2.66
EV/Core EBITDA(x) 2.79 4 3.99 4.41 3.5 11.6 8.97 5.77 5.09 5.57 9.77
Net Sales Growth(%) 10.5 1.5 28.95 8.47 8.17 -16.56 -8.78 16.95 14.64 6.55 13.86
EBIT Growth(%) 4.54 -19.68 17.4 26.84 8.76 -199.78 100.27 35177.45 101.18 -34.73 3.21
PAT Growth(%) -24.37 -18.09 23.66 50.92 18.79 -342.77 32.88 107.94 1450.72 -65.43 37.26
EPS Growth(%) -24.37 -18.09 23.65 50.93 18.8 -342.76 32.88 107.94 1450.67 -65.43 37.26
Debt/Equity(x) 0.6 0.68 0.53 0.55 0.7 1.56 2.04 1.94 1.44 1.32 1.19
Current Ratio(x) 1.23 1.08 0.91 0.96 1.21 1.14 0.8 0.9 1.11 0.77 0.68
Quick Ratio(x) 1.23 1.08 0.89 0.94 1.18 1.13 0.8 0.89 1.1 0.75 0.66
Interest Cover(x) 1.88 1.93 1.89 2.22 2.49 -2.02 0 1.11 2.06 1.54 1.79
Total Debt/Mcap(x) 2.21 1.79 0.94 0.69 1.71 5.51 6.59 1.96 1.3 0.99 0.34

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +14% +12% +8% +7%
Operating Profit CAGR +10% +7% +30% +6%
PAT CAGR +100% — — +7%
Share Price CAGR +27% +47% +57% +30%
ROE Average +7% +9% +3% +2%
ROCE Average +9% +11% +8% +7%

Choksi Laboratories Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 31.48 %
FII 10.01 %
DII (MF + Insurance) 0 %
Public (retail) 58.51 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 31.4831.4831.4831.4831.4831.4831.4831.4831.4831.48
FII 0001.944.315.695.696.037.0210.01
DII 0000000000
Public 68.5268.5268.5266.5864.2162.8362.8362.4961.558.51
Others 0000000000
Total 100100100100100100100100100100

Choksi Laboratories Peer Comparison

Business Support Edit Columns

Choksi Laboratories Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Choksi Laboratories Pros & Cons

Pros

  • Company has reduced debt.

Cons

  • Promoter holding is low: 31.48%.
  • Company has a low return on equity of 9% over the last 3 years.
  • Debtor days have increased from 408.62 to 551.15days.
  • Stock is trading at 5.3 times its book value.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp